Johan Ulander
Overview
Explore the profile of Johan Ulander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Granberg K, Sakamaki S, Larsson N, Bergstrom F, Fuchigami R, Niwa Y, et al.
J Med Chem
. 2024 Mar;
67(6):4419-4441.
PMID: 38502782
Optimization of the highly potent and selective, yet metabolically unstable and poorly soluble hRXFP1 agonist AZ7976 led to the identification of the clinical candidate, AZD5462. Assessment of RXFP1-dependent cell signaling...
2.
Tesei G, Hsiao Y, Dabkowska A, Gronberg G, Yanez Arteta M, Ulkoski D, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(2):e2311700120.
PMID: 38175863
The ionizable-lipid component of RNA-containing nanoparticles controls the pH-dependent behavior necessary for an efficient delivery of the cargo-the so-called endosomal escape. However, it is still an empirical exercise to identify...
3.
Liu K, Nilsson R, Lazaro-Ibanez E, Duan H, Miliotis T, Strimfors M, et al.
Nat Commun
. 2023 Jul;
14(1):4007.
PMID: 37414857
In terms of lipid nanoparticle (LNP) engineering, the relationship between particle composition, delivery efficacy, and the composition of the biocoronas that form around LNPs, is poorly understood. To explore this...
4.
Audagnotto M, Czechtizky W, De Maria L, Kack H, Papoian G, Tornberg L, et al.
Sci Rep
. 2022 Jun;
12(1):10018.
PMID: 35705565
Proteins exist in several different conformations. These structural changes are often associated with fluctuations at the residue level. Recent findings show that co-evolutionary analysis coupled with machine-learning techniques improves the...
5.
Geschwindner S, Ulander J
Expert Opin Drug Discov
. 2019 Sep;
14(12):1221-1225.
PMID: 31502891
No abstract available.
6.
Lemurell M, Ulander J, Emtenas H, Winiwarter S, Broddefalk J, Swanson M, et al.
J Med Chem
. 2019 Apr;
62(9):4325-4349.
PMID: 30929436
5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates have been discontinued and the link between...
7.
Pettersen D, Broddefalk J, Emtenas H, Hayes M, Lemurell M, Swanson M, et al.
J Med Chem
. 2019 Mar;
62(9):4312-4324.
PMID: 30869888
5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the production of proinflammatory and vasoactive leukotrienes. As such, they are hypothesized to have therapeutic benefit for the treatment...
8.
Fechner U, de Graaf C, Torda A, Gussregen S, Evers A, Matter H, et al.
J Cheminform
. 2017 Dec;
8(Suppl 1):18.
PMID: 29270804
No abstract available.
9.
Grebner C, Lecina D, Gil V, Ulander J, Hansson P, Dellsen A, et al.
Biophys J
. 2017 Mar;
112(6):1147-1156.
PMID: 28355542
In this study, we performed an extensive exploration of the ligand entry mechanism for members of the steroid nuclear hormone receptor family (androgen receptor, estrogen receptor α, glucocorticoid receptor, mineralocorticoid...
10.
Giordanetto F, Tyrchan C, Ulander J
ACS Med Chem Lett
. 2017 Feb;
8(2):139-142.
PMID: 28197301
Design strategies centered on intramolecular hydrogen bonds are sometime used in drug discovery, but their general applicability has not been addressed beyond scattered examples or circumstantial evidence. A total of...